Protocol Ledger

NCT05159778 · Phase II · COMPLETED

Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)

Interventional Phase II clinical trial protocol NCT05159778 sponsored by HiberCell in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-11-09 Enrollment: 26 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05159778
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)26 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05159778
Protocol FieldVerified Registry Value
NCT IdentifierNCT05159778
Consolidated Lead SponsorHiberCell
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment26 participants (ACTUAL)
Registered Start Date2021-11-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05159778
Hospital Research SiteLocationSite Profile
University of Colorado Anschutz Medical CampusAurora, COOpen Hospital Dossier ->
Moffitt Cancer CenterTampa, FLOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI